<DOC>
	<DOCNO>NCT01702714</DOCNO>
	<brief_summary>This open-label , multicenter , non-randomized , dose-escalating phase Ib study expansion cohort determine recommend Phase II dose schedule investigate safety , tolerability , activity RO5083945 combination cisplatin gemcitabine carboplatin paclitaxel patient advanced recurrent non-small cell lung cancer squamous histology receive prior chemotherapy metastatic disease . Cohorts patient receive escalate dos RO5083945 combination 6 cycle cisplatin gemcitabine carboplatin paclitaxel . Anticipated time study treatment disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study RO5083945 Combination With Cisplatin Gemcitabine Carboplatin Paclitaxel Patients With Advanced Recurrent Non-Small Cell Lung Cancer Squamous Histology Who Have Not Received Prior Chemotherapy The Metastatic Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Locally advance ( stage IIIB , exclude patient candidate chemoradiotherapy radical thoracic radiotherapy ) , metastatic ( stage IV ) recurrent squamous nonsmall cell lung cancer ( NSCLC ) Histologically document squamous NSCLC . Mixed tumor categorize accord predominant cell type Histological tumor tissue sample initial diagnosis new tumor biopsy representative disease Patients receive adjuvant chemotherapy eligible last administration prior adjuvant regimen occur least 3 month prior enrollment At least one measurable disease lesion per RECIST 1.1 criterion Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Adequate hematological , liver renal function Females childbearing potential must commit use reliable appropriate method contraception least 3 month end last dose study treatment Prior chemotherapy ( exclude neoadjuvant/adjuvant chemotherapy/chemoradiotherapy ) treatment another systemic anticancer agent ( e.g . monoclonal antibody , tyrosine kinase inhibitor ) Radiotherapy within last 4 week prior first dose , except limited field palliative radiotherapy bone pain relief Treatment investigational agent within 30 day prior start study treatment participation another clinical trial ( e.g . CTC blood collection ) within 7 day prior start study treatment Historical clinical evidence central nervous system ( CNS ) metastases ( except previously treat CNS metastases patient asymptomatic , evidence active CNS metastasis &gt; /= 3 month prior first dose requirement steroid enzymeinducing anticonvulsant last 14 day ) Recent history poorly control hypertension ( systolic &gt; 180 mmHg diastolic &gt; 100 mmHg ) Severe uncontrolled illness , include poorly control diabetes mellitus active uncontrolled infection Hypersensitivity active substance excipients study drug include premedication ( corticosteroid , antihistamine , paracetamol ) Pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>